Array BioPharma's (ARRY) Buy Rating Reaffirmed at Cantor Fitzgerald


's stock had its "buy" rating reaffirmed by investment analysts at Cantor Fitzgerald in a note issued to investors on Sunday. They currently have a $15.00 target price on the biopharmaceutical company's stock.



from Biotech News